Table 1.
Characteristics of patients with unrelated donors and HLA-identical sibling donors (12)
| Characteristic | Unrelated transplant Number (%) |
Sibling transplant Number (%) |
|---|---|---|
| HLA compatibility, n (%) | ||
| Matched a | 423 (45) | 993 (100) |
| mismatched | 395 (42) | 0 |
| unknown | 118 (13) | 0 |
| Age, median years (range) | 35 (<1 – 59) | 38 (<1–67) |
| Transplant year, n (%) | ||
| 1985–1991 | 159 (17) | 391 (39) |
| 1992–2002 | 777 (83) | 602 (61) |
| Gender match (patient/donor), n (%) | ||
| Male/Male | 329 (35) | 332 (33) |
| Male/Female | 202 (22) | 250 (25) |
| Female/Male | 234 (25) | 189 (19) |
| Female/Female | 171 (18) | 222 (22) |
| Total body irradiation, n (%) | ||
| yes | 858 (92) | 537 (54) |
| no | 78 (8) | 456 (46) |
| Disease group, n (%) b | ||
| non-malignant disease | 82 (9) | 170 (17) |
| low risk malignancy | 546 (58) | 497 (50) |
| high risk malignancy | 308 (33) | 326 (33) |
| Source of stem cells, n (%) | ||
| bone marrow | 905 (97) | 848 (85) |
| peripheral blood | 31 (3) | 145 (15) |
| Outcomes, cumulative incidence | ||
| Grades II–IV acute GVHD (day 100) | 86% | 56% |
| Grades III–IV acute GVHD (day 100) | 37% | 19% |
| Clinical extensive chronic GVHD (5 years) | 52% | 43% |
| Non-relapse mortality (5 years) | 39% | 25% |
a
patient and donor matched for HLA-A, B, C and DRB1
b
non-malignant disease: aplastic anemia, immune deficiency disorder, lymphoproliferative disease, myelodysplastic syndrome and paroxysmal nocturnal hematuria; low risk malignancy: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) or non-Hodgkin lymphoma (NHL) in remission and chronic myelogenous leukemia (CML) in chronic phase; high risk malignancy: ALL, AML, chronic lymphocytic leukemia, NHL in relapse, CML beyond chronic phase, multiple myeloma and Hodgkin’s disease.